STRO Sutro Biopharma, Inc. - Common Stock
$22,94
Prezzo · Ago 19, 2026
Fondamentali al Ago 12, 2026
Intervallo 52 sett.
$1–$44
51% of range
Rating Analisti
BUY
19 analysts
Prezzo Obiettivo
$48
+108% upside
P/E (TTM)
-1.0
ROE
232.2%
Margine di Profitto Netto
-186.5%
Informazioni su Sutro Biopharma, Inc. - Common Stock Panoramica della società da Wikipedia
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Leggi di più
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
STRO Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$22.94
Capitalizzazione di Mercato
$197M
P/E (TTM)
-1.0
EPS (TTM)
$-22.49
Ricavi (TTM)
$102M
Rendimento div.
—
ROE
232.2%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$1 – $44
STRO Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$102M
2016-12-31
→
2025-12-31
EPS
$-22.49
2020-12-31
→
2025-12-31
Flusso di cassa libero
—
2018-12-31
→
2018-12-31
Margini
-186.5%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
STRO
Mediana dei peer
P/E (TTM)
-1.0
6.1
P/S (TTM)
1.9
7.7
P/B
-1.5
2.2
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
STRO
Mediana dei peer
Operating Margin (Margine Operativo)
-154.5%
—
Net Profit Margin (Margine di Profitto Netto)
-186.5%
-60.9%
ROA
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
STRO
Mediana dei peer
Current Ratio (Rapporto corrente)
2.0
5.9
Quick Ratio
1.9
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
STRO
Mediana dei peer
Revenue YoY (Ricavi YoY)
65.2%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
14.8%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
19.1%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
STRO
Mediana dei peer
STRO Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
19 analisti
- Acquisto forte 5 26,3%
- Compra 12 63,2%
- Mantieni 1 5,3%
- Vendi 1 5,3%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
13 analisti · 2026-08-13
Mediana
$50.00
Ora
$22.94
Basso
$10.00
Alto
$61.00
Target mediano
$50.00
+118,0%
Target medio
$47.77
+108,2%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.34%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 31 Marzo 2026 | $-2.94 | $-3.85 | 0.91% |
| 31 Dicembre 2025 | $-5.29 | $-4.43 | -0.86% |
| 30 Settembre 2025 | $-6.70 | $-4.23 | -2.5% |
| 30 Giugno 2025 | $-1.40 | $-4.10 | 2.7% |
| 31 Marzo 2025 | $-9.10 | $-7.22 | -1.9% |
| 31 Dicembre 2024 | $-8.90 | $-8.48 | -0.42% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| SABS | — | — | — | — | — | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 15
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Stato Patrimoniale 24
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Efficienza 2
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Conto Economico 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
Stato Patrimoniale 23
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
Flusso di cassa 10
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
Efficienza 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
Valutazione (TTM) 12
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $102M | $62M | $154M | $68M | $62M |
| Margine Operativo % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Utile netto | $-191M | $-227M | $-107M | $-119M | $-106M |
| EPS Diluito | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | — | — | 0.0 | 0.1 | 0.1 |
| Rapporto corrente | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 111 filer · $467.3M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 46 (+21 vs trimestre precedente) | 16 (+8 vs trimestre precedente) | 20 (0 vs trimestre precedente) | 19 (+5 vs trimestre precedente) | +1.3M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.320.887 | 1.304.846 | 9,27% | Azioni |
| BVF INC/IL | $41.559.362 | 1.251.788 | 8,89% | Azioni |
| Affinity Asset Advisors, LLC | $38.926.568 | 1.172.487 | 8,33% | Azioni |
| SAMSARA BIOCAPITAL, LLC | $35.287.350 | 1.062.872 | 7,55% | Azioni |
| Kynam Capital Management, LP | $28.968.926 | 872.558 | 6,20% | Azioni |
| ORBIMED ADVISORS LLC | $24.698.941 | 743.944 | 5,29% | Azioni |
| Balyasny Asset Management L.P. | $23.610.578 | 711.162 | 5,05% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.048.071 | 694.219 | 4,93% | Azioni |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.430.698 | 585.262 | 4,16% | Azioni |
| Velan Capital Investment Management LP | $17.003.712 | 512.160 | 3,64% | Azioni |
| Woodline Partners LP | $15.206.563 | 458.029 | 3,25% | Azioni |
| ADAR1 Capital Management, LLC | $13.413.265 | 404.014 | 2,87% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $12.150.270 | 365.972 | 2,60% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $11.027.500 | 332.057 | 2,36% | Azioni |
| STATE STREET CORP | $10.158.503 | 305.979 | 2,17% | Azioni |
| Merck & Co., Inc. | $9.042.053 | 272.351 | 1,93% | Azioni |
| ACUTA CAPITAL PARTNERS, LLC | $8.972.333 | 270.251 | 1,92% | Azioni |
| AMERIPRISE FINANCIAL INC | $8.123.011 | 244.669 | 1,74% | Azioni |
| Point72 Asset Management, L.P. | $7.895.856 | 237.827 | 1,69% | Azioni |
| KVP Capital Advisors, LP | $7.522.290 | 226.575 | 1,61% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $6.696.042 | 201.688 | 1,43% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.559.058 | 197.562 | 1,40% | Azioni |
| UBS Group AG | $5.407.251 | 162.869 | 1,16% | Azioni |
| Seven Fleet Capital Management LP | $3.794.182 | 159.118 | 0,81% | Azioni |
| Qube Research & Technologies Ltd | $3.539.452 | 106.610 | 0,76% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $3.460.502 | 104.232 | 0,74% | Azioni |
| CITADEL ADVISORS LLC | $3.385.205 | 101.964 | 0,72% | Azioni |
| MACKENZIE FINANCIAL CORP | $3.146.264 | 94.767 | 0,67% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $2.865.957 | 86.324 | 0,61% | Azioni |
| MARSHALL WACE, LLP | $2.448.865 | 73.761 | 0,52% | Azioni |
| Y-Intercept (Hong Kong) Ltd | $1.855.183 | 55.879 | 0,40% | Azioni |
| Squarepoint Ops LLC | $1.843.895 | 55.539 | 0,39% | Azioni |
| XTX Topco Ltd | $1.732.011 | 52.169 | 0,37% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.636.826 | 49.302 | 0,35% | Azioni |
| Sigma Planning Corp | $1.494.664 | 45.020 | 0,32% | Azioni |
| Fisher Asset Management, LLC | $1.171.794 | 35.295 | 0,25% | Azioni |
| Elmind Capital, LP | $1.063.628 | 32.037 | 0,23% | Azioni |
| D. E. Shaw & Co., Inc. | $1.000.250 | 30.128 | 0,21% | Azioni |
| GOLDMAN SACHS GROUP INC | $975.814 | 29.392 | 0,21% | Azioni |
| Trexquant Investment LP | $917.515 | 27.636 | 0,20% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $909.116 | 27.383 | 0,19% | Azioni |
| BANK OF AMERICA CORP /DE/ | $863.897 | 26.021 | 0,18% | Azioni |
| RHUMBLINE ADVISERS | $684.845 | 20.628 | 0,15% | Azioni |
| JPMORGAN CHASE & CO | $625.079 | 18.743 | 0,13% | Azioni |
| BlackRock, Inc. | $595.276 | 17.930 | 0,13% | Azioni |
| SEI INVESTMENTS CO | $544.048 | 16.387 | 0,12% | Azioni |
| Informed Momentum Co LLC | $538.902 | 16.232 | 0,12% | Azioni |
| DEUTSCHE BANK AG\ | $516.692 | 15.563 | 0,11% | Azioni |
| RBF Capital, LLC | $507.030 | 15.272 | 0,11% | Azioni |
| WELLS FARGO & COMPANY/MN | $449.661 | 13.544 | 0,10% | Azioni |
| AJU IB Investment Co., Ltd. | $435.925 | 17.500 | 0,09% | Azioni |
| Bank of New York Mellon Corp | $434.522 | 13.088 | 0,09% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368.520 | 11.100 | 0,08% | Opzione Call |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365.200 | 11.000 | 0,08% | Opzione Put |
| MetLife Investment Management, LLC | $312.113 | 9.401 | 0,07% | Azioni |
| Walleye Capital LLC | $308.959 | 9.306 | 0,07% | Azioni |
| Integrated Quantitative Investments LLC | $296.775 | 8.939 | 0,06% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279.743 | 8.426 | 0,06% | Azioni |
| Lighthouse Investment Partners, LLC | $277.818 | 8.368 | 0,06% | Azioni |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242.792 | 7.313 | 0,05% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $242.360 | 7.300 | 0,05% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232.433 | 7.001 | 0,05% | Azioni |
| Persistent Asset Partners Ltd | $218.091 | 6.569 | 0,05% | Azioni |
| CITIGROUP INC | $216.995 | 6.536 | 0,05% | Azioni |
| Verdad Advisers, LP | $212.480 | 6.400 | 0,05% | Azioni |
| Invesco Ltd. | $211.119 | 6.359 | 0,05% | Azioni |
| HSBC HOLDINGS PLC | $205.722 | 6.234 | 0,04% | Azioni |
| TWO SIGMA ADVISERS, LP | $203.401 | 17.580 | 0,04% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $185.920 | 5.600 | 0,04% | Azioni |
| MORGAN STANLEY | $181.870 | 5.478 | 0,04% | Azioni |
| Vanguard Global Advisers, LLC | $180.774 | 5.445 | 0,04% | Azioni |
| Police & Firemen's Retirement System of New Jersey | $156.173 | 4.704 | 0,03% | Azioni |
| Nuveen, LLC | $131.837 | 3.971 | 0,03% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $119.520 | 3.600 | 0,03% | Azioni |
| Nuveen Asset Management, LLC | $103.678 | 56.347 | 0,02% | Azioni |
| BARCLAYS PLC | $84.228 | 2.537 | 0,02% | Azioni |
| NORTHERN TRUST CORP | $83.100 | 2.503 | 0,02% | Azioni |
| State of Wyoming | $53.718 | 1.618 | 0,01% | Azioni |
| Legal & General Group Plc | $51.394 | 1.548 | 0,01% | Azioni |
| Ameritas Investment Partners, Inc. | $48.074 | 1.448 | 0,01% | Azioni |
| FMR LLC | $44.388 | 1.337 | 0,01% | Azioni |
| Russell Investments Group, Ltd. | $42.330 | 1.275 | 0,01% | Azioni |
| VANGUARD GROUP INC | $36.307 | 3.138 | 0,01% | Azioni |
| Tower Research Capital LLC (TRC) | $28.751 | 866 | 0,01% | Azioni |
| Point72 Asia (Singapore) Pte. Ltd. | $26.943 | 31.026 | 0,01% | Azioni |
| CWM, LLC | $24.487 | 983 | 0,01% | Azioni |
| ROYAL BANK OF CANADA | $23.000 | 687 | 0,00% | Azioni |
| Owl Creek Wealth Partners LLC | $16.302 | 491 | 0,00% | Azioni |
| ACADIAN ASSET MANAGEMENT LLC | $12.405 | 373.839 | 0,00% | Azioni |
| Sterling Capital Management LLC | $9.329 | 281 | 0,00% | Azioni |
| Quantbot Technologies LP | $6.673 | 201 | 0,00% | Azioni |
| Physician Wealth Advisors, Inc. | $6.043 | 182 | 0,00% | Azioni |
| MERCER GLOBAL ADVISORS INC /ADV | $3.718 | 112 | 0,00% | Azioni |
| OSAIC HOLDINGS, INC. | $3.320 | 100 | 0,00% | Azioni |
| PNC Financial Services Group, Inc. | $2.058 | 62 | 0,00% | Azioni |
| Fortitude Family Office, LLC | $1.859 | 56 | 0,00% | Azioni |
| Bogart Wealth, LLC | $1.660 | 50 | 0,00% | Azioni |
| Parallel Advisors, LLC | $1.560 | 47 | 0,00% | Azioni |
| NISA INVESTMENT ADVISORS, LLC | $1.461 | 44 | 0,00% | Azioni |
| Accredited Wealth Management, LLC | $869 | 5 | 0,00% | Azioni |
Insider aziendali 27 insider · 14 dirigenti · 14 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 03 Marzo 2023 M | 164.816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 02 Giugno 2026 M | 4.725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 03 Marzo 2023 M | 87.693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 01 Dicembre 2023 A | 31.698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 18 Settembre 2023 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 Agosto 2023 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 12 Luglio 2023 M | 24.988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 01 Maggio 2023 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 Aprile 2023 M | 100.368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 15 Marzo 2023 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 03 Marzo 2023 M | 40.827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 03 Marzo 2023 M | 52.690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 05 Marzo 2022 M | 37.736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 Gennaio 2019 A | — | 0 | 0 | $0 |
| Heidi Hunter | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| Michael Dybbs | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| Daniel H Petree | Direttore | 05 Giugno 2026 A | 18.601 | 0 | 0 | $0 |
| Connie Matsui | Direttore | 05 Giugno 2026 A | 50.000 | 1 | 0 | $40.000 |
| James P Panek | Direttore | 05 Giugno 2026 A | — | 0 | 0 | $0 |
| John Gordon Freund | Direttore | 08 Giugno 2023 A | 56.327 | 0 | 0 | $0 |
| Shalini Sharp | Direttore | 06 Giugno 2022 A | — | 0 | 0 | $0 |
| Daniel Janney | Direttore | 17 Giugno 2019 A | 1.944.901 | 0 | 0 | $0 |
| Michael Jay Ross | Direttore | 01 Ottobre 2018 C | 18.248 | 0 | 0 | $0 |
| Bryan V Lawlis | Direttore | 26 Settembre 2018 A | — | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 09 Ottobre 2018 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 15 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 3.826 SH | 08 Agosto 2026 | Giornaliero |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,25% | 28.745 SH | 08 Agosto 2026 | Giornaliero |
| IWC · iShares Trust | 0,09% | 54.216 SH | 08 Agosto 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11.715 SH | 08 Agosto 2026 | Giornaliero |
| IWN · iShares Trust | 0,02% | 121.308 SH | 08 Agosto 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91.894 SH | 08 Agosto 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 16.520 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,01% | 398.610 SH | 08 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177.152 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,01% | 47.358 SH | 08 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,00% | 22.665 SH | 08 Agosto 2026 | Giornaliero |
| ITOT · iShares Trust | 0,00% | 29.451 SH | 08 Agosto 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501.524 SH | 08 Agosto 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.670 SH | 08 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.330 SH | 08 Agosto 2026 | Giornaliero |